GKB Ophthalmics Intrinsic Value
GKB Ophthalmics intrinsic value. GKB Ophthalmics (GKB) median intrinsic value is ₹74.27 from 9 valuation models (range ₹19–₹157), vs current price ₹62.96 — +18.0% upside (Trading Below Median Value), margin of safety 15.2%. Read GKB dividend history for the complete payout history and dividend yield track record.
GKB Valuation Methods Summary — DCF, Graham Number & P/E
GKB Ophthalmics intrinsic value across 9 models vs current price ₹62.96 — upside/downside and value range per method. Compare with GKB fair price to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹33.44 | ₹26.75 - ₹40.13 | -46.9% | EPS: ₹1.52, Sector P/E: 22x |
| Book Value Method | asset | ₹157.40 | ₹141.66 - ₹173.14 | +150.0% | Book Value/Share: ₹110.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹125.92 | ₹113.33 - ₹138.51 | +100.0% | Revenue/Share: ₹248.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹125.92 | ₹113.33 - ₹138.51 | +100.0% | EBITDA: ₹8.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹74.27 | ₹59.42 - ₹89.12 | +18.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹18.89 | ₹17.00 - ₹20.78 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹23.48 | ₹21.13 - ₹25.83 | -62.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹80.00 | ₹72.00 - ₹88.00 | +27.1% | ROE: 7.3%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹61.34 | ₹55.21 - ₹67.47 | -2.6% | EPS: ₹1.52, BVPS: ₹110.00 |
GKB Intrinsic Value vs Market Price — All Valuation Models
GKB Ophthalmics fair value range ₹19–₹157 vs current market price ₹62.96 across 9 valuation models. For current market price and key ratios, visit GKB Ophthalmics stock price NSE.
GKB Intrinsic Value Analysis — Undervalued or Overvalued?
GKB Ophthalmics median intrinsic value ₹74.27, current price ₹62.96 — Trading Below Median Value by 18.0%, margin of safety 15.2%.
What is the intrinsic value of GKB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of GKB Ophthalmics (GKB) is ₹74.27 (median value). With the current market price of ₹62.96, this represents a +18.0% variance from our estimated fair value.
The valuation range spans from ₹18.89 to ₹157.40, indicating ₹18.89 - ₹157.40.
Is GKB undervalued or overvalued?
Based on our multi-method analysis, GKB Ophthalmics (GKB) appears to be trading below median value by approximately 18.0%.
GKB Financial Health — Key Ratios vs Industry Benchmarks
GKB Ophthalmics financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 18.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 7.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 5.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.94x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GKB Cash Flow Quality — Operating & Free Cash Flow
GKB Ophthalmics operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-4 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹5 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |